Skip to content

Ascendis Pharma A/S

US · ASND #1127 by market cap Listed 2015
252.73 -3.23 -1.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Morgan Stanley Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $273
    Market Newswire · 2026/10/19
  • Rating change
    CCORF Initiates Ascendis Pharma A/S(ASND.US) With Hold Rating, Announces Target Price $268
    Market Newswire · 2026/10/26
  • Rating change
    H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $335
    Market Newswire · 2026/11/13
  • Rating change
    Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273
    Market Newswire · 2026/11/3
  • Ascendis Pharma A/S(ASND.US) Officer Sells US$5.28 Million in Common Stock
    Market Newswire · 2026/11/19
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Argenx Se (ARGX) and Hinge Health, Inc. Class A (HNGE)
    TipRanks · 2026/10/12
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Fractyl Health, Inc. (GUTS) and Ascendis Pharma (ASND)
    TipRanks · 2026/10/19
  • Form 144 | Ascendis Pharma A/S(ASND.US) Officer Proposes to Sell 5.28 Million in Common Stocks
    Market Newswire · 2026/11/18
  • Rating change
    Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $273
    Market Newswire · 2026/11/9
  • Citi Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $335
    Market Newswire · 2026/11/16
  • Rating change
    UBS Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $269
    Market Newswire · 2026/10/16
  • Rating change
    BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating
    Market Newswire · 2026/10/9
  • Rating change
    TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $341
    Market Newswire · 2026/11/11
  • Rating change
    Citi Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $330
    Market Newswire · 2026/10/26
  • Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $341
    Market Newswire · 2026/11/16
  • Rating change
    UBS Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $269
    Market Newswire · 2026/10/15
  • Rating change
    H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $344
    Market Newswire · 2026/11/9
  • A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $274 to $356
    Market Newswire · 2026/11/14
  • Rating change
    RBC Capital Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $290
    Market Newswire · 2026/10/9
  • Rating change
    Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $329
    Market Newswire · 2026/9/30
  • Rating change
    A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $273 to $344
    Market Newswire · 2026/9/2
  • Rating change
    Raymond James Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $287
    Market Newswire · 2026/9/15
  • Rating change
    H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $344
    Market Newswire · 2026/8/31
  • Rating change
    Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275
    Market Newswire · 2026/8/31
  • Rating change
    Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312
    Market Newswire · 2026/9/3

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Ascendis Pharma A/S discussion 0 comments

Add a comment